Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mariam Lotfy Khaled has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Design, synthesis, molecular docking and molecular dynamics simulations of pyrazolo[3,4- d ]pyrimidine scaffolds as selective COX-2 and CDK2 kinase inhibitors with dual anti-inflammatory and anti-proliferative activities

    by Sara Y. Ewieda, Laila Ziko, Ahmed Elshewy, Mo'MEn Salem, Mohammed L. Ibrahim, Mariam Lotfy Khaled, Mohnad Abdalla, Wafa Ali Eltayb, Mohamed R. Elnagar, Mohamed M. Tawfik, et al.

    A new series of pyrazolo[3,4- d ]pyrimidine scaffolds, namely, 4a–l, were designed and synthesized. Compound 4g displayed advanced COX-2 selectivity as well as CDK2 inhibitory activity.


  • Open Access

    Possible Role of Endothelial-Derived Cellular and Exosomal-miRNAs in Lipid-Mediated Diabetic Retinopathy: Microarray Studies

    by Khaled Elmasry, Samar Habib, Inas Helwa, Mariam Lotfy Khaled, Ahmed S. Ibrahim, Amany Tawfik, Mohamed Al-Shabrawey

    Diabetic retinopathy (DR) is a salient cause of blindness worldwide. There is still an immense need to understand the pathophysiology of DR to discover better diagnostic and therapeutic modalities. Human retinal endothelial cells (HRECs) were treated with 15-HETE or D-glucose, then miRNAs were isolated, and a microarray was performed. MirWALK 2 and Ingenuity Pathway Analysis (IPA) were used to analyze the microarray results. Exosomal miRNAs from 15-HETE-treated HRECs were isolated, microarrayed, and then imported into IPA for further analysis. The microarray results showed that 15-HETE downregulated 343 miRNAs and upregulated 297 miRNAs in HRECs. High glucose treatment induced a differential expression of HREC-miRNAs where 185 miRNAs were downregulated and 244 were upregulated. Comparing the impact of 15-HETE versus DG or diabetic mouse retina elaborated commonly changing miRNAs. Pathway and target analysis for miRNAs changed in 15-HETE-treated HRECs revealed multiple targets and pathways that may be involved in 15-HETE-induced retinal endothelial dysfunction. The HREC-exosomal miRNAs were differentially expressed after 15-HETE treatment, with 34 miRNAs downregulated and 45 miRNAs upregulated, impacting different cellular pathways. Here, we show that 15-HETE induces various changes in the cellular and exosomal miRNA profile of HRECs, highlighting the importance of targeting the 12/15 lipoxygenase pathway in DR.


  • Open Access

    Leptomeningeal Disease (LMD) in Patients with Melanoma Metastases

    by Mariam Lotfy Khaled, Ahmad A. Tarhini, Peter A. Forsyth, Inna Smalley, Yolanda Piña

    Leptomeningeal disease (LMD) is a devastating complication caused by seeding malignant cells to the cerebrospinal fluid (CSF) and the leptomeningeal membrane. LMD is diagnosed in 5–15% of patients with systemic malignancy. Management of LMD is challenging due to the biological and metabolic tumor microenvironment of LMD being largely unknown. Patients with LMD can present with a wide variety of signs and/or symptoms that could be multifocal and include headache, nausea, vomiting, diplopia, and weakness, among others. The median survival time for patients with LMD is measured in weeks and up to 3–6 months with aggressive management, and death usually occurs due to progressive neurologic dysfunction. In melanoma, LMD is associated with a suppressive immune microenvironment characterized by a high number of apoptotic and exhausted CD4+ T-cells, myeloid-derived suppressor cells, and a low number of CD8+ T-cells. Proteomics analysis revealed enrichment of complement cascade, which may disrupt the blood–CSF barrier. Clinical management of melanoma LMD consists primarily of radiation therapy, BRAF/MEK inhibitors as targeted therapy, and immunotherapy with anti-PD-1, anti-CTLA-4, and anti-LAG-3 immune checkpoint inhibitors. This review summarizes the biology and anatomic features of melanoma LMD, as well as the current therapeutic approaches.


  • Genetics of keratoconus

    by Mariam Lotfy Khaled, Yutao Liu